← Leaderboards
Charles Morrison
Family Health International
$9,413,020
Attributed
$12,240,387
Total exposure
6
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.6M · FY2006–21$2M$1.5M$1M$500K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
Funding mix
By agency
NIH$12,240,387 · 6
By mechanism
N01$6,873,144 · 1
R01$4,905,776 · 3
R21$353,650 · 1
R34$107,817 · 1
Top collaborators
- Raina N Fichorova5 shared
- Jennifer Caraway Deese3 shared
- Lindi Masson3 shared
- Janet Patricia Hapgood2 shared
- Kavita Nanda1 shared
- Helen Rees1 shared
Most similar at Family Health International
Same institution · by research overlap
- Jennifer Caraway Deese$1,604,238
- Lindi Masson$1,434,257
- Paul J Feldblum$138,000
- Kavita Nanda$250,089
- Morrison Charles$1,550,708
Others in their field
Top investigators on “Woman”
- Chanza Baytop · Westat, Inc.$271,217,917
- Lawrence Corey · Fred Hutchinson Cancer Center$252,110,127
- Wafaa M. El-Sadr · Columbia University Health Sciences$232,152,340
- Myron S Cohen · Family Health International$208,921,087
- Barbara Driver · Westat, Inc.$190,429,693
- Judith S. Currier · University Of California Los Angeles$149,317,678
Research focus
WomanInjectableContraceptive MethodsContraceptive AgentsProgestinsMedroxyprogesterone 17-AcetateHormonal ContraceptionHiv InfectionsBiologicalImmuneInfectionAffectHormonesHigh PrevalenceSamplingCounselingParticipantCervix UteriInflammationComplexImmunityConflict (Psychology)HormonalHuman Herpesvirus 2
Grant awards (15)
Expansion of Microbiome and Immune Mediator Analysis to Include HIV Acquisition in a Case-Control Study$612,303
R01 · FY2021 · HD · contact PI
Understanding the Impact of Lower Dose Medroxyprogesterone Acetate on Female Genital Tract Microbiome and Immunology$601,007
R01 · FY2021 · HD · contact PI
Biological effects, hormone levels and mechanisms relevant to HIV-1 infection for women randomized to the injectable contraceptives depo-medroxyprogesterone acetate or norethisterone enanthate.$347,450
R01 · FY2021 · AI
Understanding the Impact of Lower Dose Medroxyprogesterone Acetate on Female Genital Tract Microbiome and Immunology$602,299
R01 · FY2020 · HD · contact PI
Biological effects, hormone levels and mechanisms relevant to HIV-1 infection for women randomized to the injectable contraceptives depo-medroxyprogesterone acetate or norethisterone enanthate.$349,856
R01 · FY2020 · AI
Innate immunity predictors of HIV: the role of contraception, pregnancy and HSV-2$434,605
R01 · FY2017 · HD · contact PI
Innate immunity predictors of HIV: the role of contraception, pregnancy and HSV-2$455,489
R01 · FY2016 · HD · contact PI
Innate immunity predictors of HIV: the role of contraception, pregnancy and HSV-2$484,828
R01 · FY2015 · HD · contact PI
Innate immunity predictors of HIV: the role of contraception, pregnancy and HSV-2$503,255
R01 · FY2014 · HD · contact PI
Innate immunity predictors of HIV: the role of contraception, pregnancy and HSV-2$514,684
R01 · FY2013 · HD · contact PI
A Randomized Trial of the Copper IUD versus DMPA for HIV Prevention in Women$107,817
R34 · FY2012 · HD · contact PI
Hormonal Contraception and HIV Acquisition: An IPD Meta-analysis$96,450
R21 · FY2012 · HD · contact PI
Hormonal Contraception and HIV Acquisition: An IPD Meta-analysis$257,200
R21 · FY2011 · HD · contact PI
HORMONAL CONTRACEPTION and RISK OF HIV ACQUISITION-275003310-275003310$0
N01 · FY2006 · HD · contact PI
HORMONAL CONTRACEPTION &RISK OF HIV ACQUISITION$6,873,144
N01 · FY2000 · HD